SCHEMBL3774685

SCHEMBL3774685

C=CCN1CCC(c2cccc(F)c2C)CC1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.41
SIGMAR1 Q99720 1/20 0.40
DRD2 P14416 4/20 0.39
DRD3 P35462 2/20 0.39
GRM2 Q14416 1/20 0.39
TAAR1 Q96RJ0 2/20 0.38
SLC6A4 P31645 1/20 0.38
CYP2D6 P10635 1/20 0.38
OPRL1 P41146 1/20 0.36
KCNH2 Q12809 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
HTR2C P28335 1/20 0.35
OPRD1 P41143 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3766106 0.86 SIGMAR1 (0.44) DRD4SIGMAR1DRD2DRD3GRM2
SCHEMBL5506620 0.86 DRD2 (0.44) SIGMAR1DRD2DRD3SLC6A4
SCHEMBL2781249 0.83 SIGMAR1 (0.40) DRD4SIGMAR1DRD2DRD3GRM2
SCHEMBL3764528 0.83 ADRA2A (0.48) SIGMAR1DRD2SLC6A4OPRL1ADRA2A
SCHEMBL2781898 0.83 SIGMAR1 (0.40) DRD4SIGMAR1DRD2DRD3GRM2
SCHEMBL3774468 0.83 OPRL1 (0.43) SIGMAR1DRD2CYP2D6OPRL1ADRA2A
SCHEMBL2784637 0.83 DRD3 (0.42) SIGMAR1DRD2DRD3GRM2SLC6A4
SCHEMBL3767627 0.82 DRD2 (0.44) DRD4DRD2DRD3GRM2TAAR1
SCHEMBL2783494 0.81 RBP4 (0.43) SIGMAR1GRM2CYP2D6
SCHEMBL5503809 0.81 RBP4 (0.46) DRD2DRD3SLC6A4OPRL1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851629-B2 Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2010-12-14 US claimed
EP-1768958-B1 NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION NSAB AF NEUROSEARCH SWEDEN AB (DK) 2009-11-18 EP claimed
US-20070179185-A1 NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2007-08-02 US claimed
US-7851629-B2 Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2010-12-14 US disclosed
EP-1768958-B1 NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION NSAB AF NEUROSEARCH SWEDEN AB (DK) 2009-11-18 EP disclosed
US-20070179185-A1 NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179185-A1 NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION DRD2, DRD4, HTR4 DRD4 2/4885SIGMAR1 89/4885DRD2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.